Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13504575 | 1.00 | GPR139 (0.47) | GPR139NTSR1MEN1KMT2ALMNA | |
| SCHEMBL13504604 | 0.89 | ALDH1A1 (0.43) | LMNANPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL3571714 | 0.89 | ALDH1A1 (0.43) | LMNANPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL3561695 | 0.84 | MEN1 (0.40) | GPR139MEN1KMT2ANPC1RAB9A | |
| SCHEMBL13504606 | 0.84 | MEN1 (0.40) | GPR139MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3570944 | 0.82 | NPC1 (0.44) | NPC1RAB9APKMSMN1; SMN2L3MBTL1 | |
| SCHEMBL13504569 | 0.82 | NPC1 (0.44) | NPC1RAB9APKMSMN1; SMN2L3MBTL1 | |
| SCHEMBL3566394 | 0.79 | ALDH1A1 (0.42) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL3566396 | 0.79 | ALDH1A1 (0.42) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL13504645 | 0.77 | HPGD (0.43) | MEN1KMT2ALMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742904-B1 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | UNIV CALIFORNIA (US) | 2012-10-31 | — | — | EP | claimed |
| US-20080064748-A1 | Substituted enaminones, their derivatives and uses thereof | OXFORD FINANCE CORPORATION | 2008-03-13 | — | — | US | claimed |
| EP-1742904-B1 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | UNIV CALIFORNIA (US) | 2012-10-31 | — | — | EP | disclosed |
| US-7825278-B2 | Substituted enaminones, their derivatives and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080064748-A1 | Substituted enaminones, their derivatives and uses thereof | OXFORD FINANCE CORPORATION | 2008-03-13 | — | — | US | disclosed |
| EP-1742904-A4 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | UNIV CALIFORNIA (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1494629-B1 | CONDOM | FUTURA MEDICAL DEV LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| EP-1742904-A2 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1379203-B1 | CONDOM WITH AN ERECTOGENIC COMPOSITION | FUTURA MEDICAL DEV LTD (GB) | 2006-03-01 | — | — | EP | disclosed |
| WO-2005108347-A2 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050076916-A1 | Condom | FUTURA MEDICAL DEVELOPMENTS LIMITED (GB) | 2005-04-14 | — | — | US | disclosed |
| EP-1494629-A2 | CONDOM | Futura Medical Developments Limited (GB) | 2005-01-12 | — | — | EP | disclosed |
| US-6840244-B2 | Condom with an erectogenic composition | FUTURA MEDICAL DEVELOPMENTS LIMITED (GB) | 2005-01-11 | — | — | US | disclosed |
| US-20040103902-A1 | Condom with an erectogenic composition | FUTURA MEDICAL DEVELOPMENT LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
| EP-1379203-A1 | CONDOM WITH AN ERECTOGENIC COMPOSITION | Futura Medical Developments Limited (GB) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003088880-A2 | CONDOM | FUTURA MEDICAL DEVELOPMENTS LIMITED (GB) | 2003-10-30 | — | — | WO | disclosed |
| WO-2002078580-A1 | CONDOM WITH AN ERECTOGENIC COMPOSITION | FUTURA MEDICAL DEVELOPMENTS LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064748-A1 | Substituted enaminones, their derivatives and uses thereof | GABRB2, GABRB1, GABRB3 | GPR139 395/4885NTSR1 152/4885MEN1 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.